<DOC>
	<DOCNO>NCT01345929</DOCNO>
	<brief_summary>This Phase 3 , multicenter , prospective , randomize , double-blind , double dummy study CXA 201 IV infusion ( 1500 mg q8h ) versus levofloxacin IV infusion ( 750 mg qd ) treatment adult cUTI ( include pyelonephritis ) .</brief_summary>
	<brief_title>Study Comparing Safety Efficacy Intravenous CXA-201 Intravenous Levofloxacin Complicated Urinary Tract Infection , Including Pyelonephritis</brief_title>
	<detailed_description>Approximately 500 subject enrol study randomize 1:1 receive CXA-201 comparator ( levofloxacin ) result 250 subject per treatment arm . Subject participation require minimum commitment 35 day maximum 42 day . Subjects hospitalized administration dose IV study therapy . A test cure visit occur 7 day last dose study drug late follow-up evaluation contact occur minimum 28 day maximum 35 day last dose study drug .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Pyelonephritis</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>1 . Provide write informed consent prior studyrelated procedure part normal medical care ( legally acceptable representative may provide consent subject unable , provide approve local country institution specific guideline ) . 2 . Be male females ≥ 18 year age 3 . If female , subject nonlactating , either : 1 . Not childbearing potential , defined postmenopausal least 1 year surgically sterile due bilateral tubal ligation , bilateral oophorectomy , hysterectomy ; 2 . Of childbearing potential practice barrier method birth control ( e.g. , diaphragm contraceptive sponge ) along 1 follow method : oral parenteral contraceptive ( 3 month prior study drug administration ) , vasectomized partner . Or , subject practice abstinence sexual intercourse . Subjects must willing practice method duration trial least 35 day last dose study medication . 4 . Males require practice reliable birth control method ( condom barrier device ) conduct study least 35 day last dose study medication . 5 . Pyuria ( white blood cell [ WBC ] count &gt; 10/μL unspun urine ≥ 10 per high power field spun urine ) . 6 . Clinical sign and/or symptom cUTI , either : 1 . Pyelonephritis , indicate least 2 follow : Documented fever ( oral temperature &gt; 38°C ) accompany patient symptom rigor , chill , `` warmth '' ; Flank pain ; Costovertebral angle tenderness suprapubic tenderness physical exam ; nausea vomiting ; OR 2 . Complicated low UTI , indicate least 2 follow : At least 2 follow new worsen symptoms cUTI : Dysuria ; urinary frequency urinary urgency ; Documented fever ( oral temperature &gt; 38°C ) accompany patient symptom rigor , chill , `` warmth '' ; Suprapubic pain flank pain ; Costovertebral angle tenderness suprapubic tenderness physical exam ; Nausea vomiting ; plus , At least 1 follow complicate factor : Males document history urinary retention ; Indwelling urinary catheter schedule remove IV study therapy EOT ; Current obstructive uropathy schedule medically surgically relieve IV study therapy EOT ; Any functional anatomical abnormality urogenital tract ( include anatomic malformation neurogenic bladder ) void disturbance result least 100 mL residual urine . 7 . Have pretreatment baseline urine culture specimen obtain within 24 hour start administration first dose study drug . NOTE : Subjects may enrol study start IV study drug therapy Investigator know result baseline urine culture . 8 . Require IV antibacterial therapy treatment presume cUTI . 1 . Have document history moderate severe hypersensitivity allergic reaction βlactam quinilone antibacterial ( Note : βlactams , history mild rash follow uneventful reexposure contraindication enrollment ) 2 . Have concomitant infection time randomization , require nonstudy systemic antibacterial therapy addition IV study drug therapy . ( Drugs grampositive activity [ e.g. , vancomycin , linezolid ] allow . ) 3 . Receipt amount potentially therapeutic antibacterial therapy collection pretreatment baseline urine culture administration first dose study drug . 4 . Receipt dose potentially therapeutic antibacterial agent treatment current UTI within 48 hour studyqualifying pretreatment baseline urine obtain ( exception : subject active cUTI receive prior antibiotic may enrol provide minimum 48 hour elapse last dose prior antibiotic time obtain baseline urine specimen . Subjects receive current antibiotic prophylaxis cUTI present sign symptom consistent active new cUTI may enrol provide eligibility criterion meet include obtain pretreatment qualify baseline urine culture ) . 5 . Intractable urinary infection baseline Investigator anticipate would require 7 day study drug therapy . 6 . Complete , permanent obstruction urinary tract . 7 . Confirmed fungal urinary tract infection time randomization ( ≥ 103 fungal CFU/mL ) . 8 . Permanent indwell bladder catheter urinary stent include nephrostomy . 9 . Suspected confirm perinephric intrarenal abscess . 10 . Suspected confirmed prostatitis . 11 . Ileal loop know vesicoureteral reflux . 12 . Severe impairment renal function include estimate CrCl &lt; 30 mL/min , requirement peritoneal dialysis , hemodialysis hemofiltration , oliguria ( &lt; 20 mL/h urine output 24 hour ) . 13 . Current urinary catheter schedule remove EOT ( intermittent straight catheterization IV study drug administration period acceptable ) . 14 . Any condition circumstance , opinion Investigator , would compromise safety subject quality study data . 15 . Any rapidly progressing disease immediately lifethreatening illness include acute hepatic failure , respiratory failure , septic shock . 16 . Immunocompromising condition , include establish AIDS , hematological malignancy , bone marrow transplantation , immunosuppressive therapy include cancer chemotherapy , medication prevention organ transplantation rejection , administration corticosteroid equivalent great 40 mg prednisone per day administer continuously 14 day precede randomization . 17 . One follow laboratory abnormality baseline specimen : aspartate aminotransferase ( AST [ SGOT ] ) , alanine aminotransferase ( ALT [ SGPT ] ) , alkaline phosphatase , total bilirubin level great 3 time upper limit normal ( ULN ) , absolute neutrophil count less 500/μL , platelet count less 40,000/μL , hematocrit le 20 % . 18 . Participation clinical study investigational product within 30 day prior propose first day study drug . 19 . Previous participation study CXA101 CXA201 . 20 . Women pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>cUTI</keyword>
</DOC>